This study will assess the comparative effectiveness of extended release injectable naltrexone (XR-NTX) versus buprenorphine-naloxone (BUP-NX) as pharmacotherapeutic aids to recovery amongst treatment-seeking heroin- and/or prescription opioid-dependent participants.  The primary goal of the study is to estimate the difference, if one exists, between XR-NTX and BUP-NX in the distribution of the time to relapse during the 6-month trial.

CTN Protocol ID: 
CTN-0051
Enrollment Status: 
Completed
ClinicalTrials.gov ID: 

Principal Investigator(s): 

John Rotrosen, M.D.
Professor
NYU School of Medicine
Department of Psychiatry
One Park Avenue, 8th Floor
New York, NY 10016
john.rotrosen@nyumc.org

-->